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Aim: This study aimed to H[SORUHFRPPXQLW\SKDUPDFLVWV¶UROHVRQVFUHHQLQJIor risk factors, 
providing safety information related NSAIDs to patients  
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely dispensed without 
prescription from pharmacies in Thailand, while they are frequently reported as causing 
adverse events. 
Methods: Self-administered questionnaires were distributed to all accredited pharmacies in 
Thailand, inviting the main pharmacist in each pharmacy to participate in this study. 
Findings: Out of 406 questionnaires distributed, 159 were returned (39.2%). Almost all 
pharmacists claimed to engage in NSAID dispensing practice, but not all of them provided 
relevant good practice, such as, screening for risk factors (56.3%-95.5%), communication on 
ADRs (36.9%-63.2%) and ADR-management (58.9%-79.7%), History of gastrointestinal (GI) 
problems was frequently mentioned for screening, but many pharmacists did not screen for 
history of NSAID use (24.7%-35.5%), older age (45.2%-48.9%), concomitant drug (63.7%), 
and problems of cardiovascular (CV) (24.1%), renal (34.9%-43.3%), and liver systems (60.3%-
61.0%). Male pharmacists were significantly less likely to inform users of non-selective 
NSAIDs about ADRs (Odd ratio (OR) 0.44), while provision of information about selective 
NSAID ADRs was higher among pharmacy owners (OR 2.28), pharmacies with more 
pharmacists (OR 3.18) and lower in pharmacies with assistants (OR 0.41). Screening for risk 
factors, and risk communication about NSAIDs were not generally conducted in Thai 
accredited community pharmacists, nor were NSAID complications fully communicated. 
Promoting of community pharmacists' roles in NSAID dispensing should give priority to 
improving, especially in high-risk patients for taking NSAIDs. 
Key words: Community pharmacists; Accreditation pharmacy; Non-steroidal anti-




Pain and inflammatory conditions affect large proportions of patients in both high and lower 
income countries, especially in females and those of older age (Tsang et al., 2008). NSAIDs 
are important for the management of these conditions, acting by inhibition of the 
cyclooxygenase (COX) enzymes, and are widely used in the community (Rao & Knaus, 2008; 
Brune and Patrignani, 2015). NSAIDs can potentially induce significant complications 
involving the gastro-intestinal (GI), cardiovascular (CV) and renal systems (Wehling, 2014). 
NSAID use is widespread and all healthcare professionals have a duty to identify 
whether patients have factors potentially increasing the risk of adverse effects before supplying 
them. In practice, however, studies in several countries show frequent prescribing of NSAIDs 
in patients with risk factors such as diabetes, hypertension, heart diseases, GI problems (Al-
Shidhani et al., 2015), chronic kidney disease (Ingrasciotta et al., 2014; Meuwesen et al., 
2016). Their use is also common in older patients (Hanlon et al., 2002) and in combination 
with drugs likely to cause serious drug-drug interactions (Hersh et al., 2007). Furthermore, 
SDWLHQWV¶DZDUHQHVVRIthe risks of NSAIDs is lower than desirable (Wilcox et al., 2005; Cullen 
et al., 2006; Stosic et al., 2011) and their perceptions concerning these risks is much lower than 
that of healthcare professionals (Bongard et al., 2002; Cullen et al., 2006). The lack of 
knowledge about possible adverse drug reactions (ADRs) may be influenced by the ease with 
which NSAIDs can be purchased (Cullen et al., 2006). 
Community pharmacies are an important source of NSAID supply, so pharmacists 
should screen potential purchasers and those presenting prescriptions (Mangum et al., 2003) 
for risk factors and provide safety information about these products. Community pharmacy-
based interventions in relation to NSAIDs can prevent serious long-term problems, including 
acute kidney injury (Pai, 2015) and gastrointestinal complications (Ibañez-Cuevas et al., 2008; 
Teichert et al., 2014), as well as impacting positively on patient knowledge (Jang et al., 2011). 
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In Thailand, NSAIDs were the second most frequently reported drugs in the 
spontaneous reporting system for ADRs between 1984 and 2017 (Health Product Vigilance 
Center, 2018). National health surveys found that 20% of people take a painkiller 2-3 days per 
week including NSAIDs (Akepalakorn, 2009). Moreover, a recent study reported that 30% of 
people in rural areas use NSAIDs often (Luanghirun et al., 2017). The prevalence of NSAID 
use in Thailand is similar to that in the United States (Zhou et al., 2014), but Thai patients can 
obtain NSAIDs without prescription from pharmacies, even those not classified as over the 
counter (OTC) drugs in Thailand. Unlike many countries, Thailand has no guidelines 
concerning risk screening and information provision to inform best practice for pharmacists. 
Moreover, little work has studied the practices of community pharmacists in Thailand. Our 
previous survey in Thai hospital out-patients found they had poor knowledge about the risks 
of taking NSAIDs (Phueanpinit et al., 2016). Hence this survey aimed to determine community 
SKDUPDFLVWV¶ self-reported practices in screening patients for risk factors prior to supplying 
NSAIDs and providing information about potential ADRs and their management. 
Methods 
Study design and setting 
A cross-sectional survey involving community pharmacists was carried out in Thailand over a 
5-month period. Community pharmacists may work in pharmacies or be pharmacy owners. 
The total number of pharmacies allowed to operate by the Thai Food and Drug Administration 
(Thai FDA) was obtained from The Bureau of Drug Control, Ministry of Public Health. From 
a total of 10,176 pharmacies in Thailand, 406 (4%) pharmacies were certificated as being 
µDFFUHGLWHG¶ An accredited pharmacy is one which has attained a mark of quality awarded by 
the Pharmacy Council, which requires they conform to five important criteria in addition to 
general mandatory control by the Thai FDA. These are: accessible location close to primary 
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health care centres, equipment, personnel, professional ethics and good quality pharmaceutical 
services, including screening, diagnosis and counselling. The standard of practice in these 
pharmacies is thus higher than in non-accredited pharmacies and importantly also requires that 
a pharmacist is present on site at all times (which is not the case for non-accredited pharmacies). 
Therefore, as there is no guarantee that a pharmacist would be able to respond to the survey in 
non-accredited pharmacies, this study involved only accredited pharmacies.  
Questionnaire development 
A questionnaire was developed in two parts; demographic data (sex, age, educational level, 
work experience, type of pharmacy, pharmacy owner, number of staff in pharmacy, number of 
SDWLHQWVSHUGD\ZRUNLQJWLPHKDYHLQWHUQVKLSSURJUDPDQGSKDUPDFLVWV¶UROHLQsupplying 
NSAIDs. The latter section consisted of nine questions covering: screening patients at risk, 
assessment of the necessity for using NSAIDs, communicating potential adverse effects, advice 
on how to manage and prevent ADRs, asking about current drug use, herbs and supplements, 
and advice on the things that patients should or should not do while taking NSAIDs. Each 
question provided options related to frequency of practice (regularly, occasionally, or never), 
plus, for those indicating they provide screening risk of ADRs, ADR communication, and ADR 
management, additional details were requested. Content validity was conducted by three 
pharmacists, and the questionnaire was subsequently piloted in ten community pharmacists 
working in non-accredited pharmacies. 
Data collection 
A questionnaire with covering letter explaining the objectives of study was sent to all 406 
community pharmacies by mail: 39 located in the northern region, 67 in the northeastern 
region, 34 in the eastern region, 12 in the western region, 59 in southern region, and 195 in the 
central region. The pharmacists in charge were requested to return the questionnaire within 3 
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weeks. If the questionnaire was not returned within two weeks, reminder cards were sent to 
non-respondents. 
Statistical analysis 
The data from returned questionnaires were analysed using IBM SPSS version 19.0.  Frequency 
of practice was dichotomised into regular and not regular. Chi-VTXDUHWHVW)LVKHU¶VH[DFWWHVW
and Independent t-test were used to explore the associations between demographic variables 
and roles in screening for risk factors, providing ADR information, and ADR management 
related to NSAIDs, where appropriate.  
Results 
Response rate and demographic details  
From the 406 questionnaires distributed, 159 were returned and analysable (response rate 
39.2%). The majority of respondents were working in independently-owned pharmacies 
(N=114, 71.7%), and were female (N=104, 65.4%). The average age was 37.2 ± 11.42 years 
(range 23 to 73 years). More than half the pharmacists had more than 5 years practice 
experience in community pharmacy (N=92, 57.9%). Just over half were pharmacy owners 
(N=90, 56.6%) and most pharmacies were located in urban areas (N=125, 78.6%). Other 
characteristics are shown in Table 1.  
(Insert Table 1) 
7KH IUHTXHQF\ RI FRPPXQLW\ SKDUPDFLVWV¶ self-reported practice roles in supplying 
NSAIDs are illustrated in Table 2. Almost all claimed to regularly or occasionally determine 
the need for an NSAID and explain to patients what they should or should not do while using 
NSAIDs. Less than a third claimed to seek information about concomitant drugs and 
supplements on a regular basis. While all  claimed to screen patients for risk factors before 
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supplying non-selective NSAIDs, the proportion indicating doing so was slightly lower for 
supply of selective COX-2 NSAIDs (N=146, 96.7%).  
(Insert Table 2) 
Similarly, fewer indicated that they regularly communicated about ADR and provided 
advice on managing and preventing adverse effects s of selective NSAIDs compared to non-
selective NSAIDs. Details of the screening which community pharmacists claimed to perform 
before dispensing are presented in Table 3, which differed slightly between the two classes of 
NSAID. In univariate analysis, no significant factor was related to screening practices for 
NSAID risks. 
(Insert Table 3) 
Provision of NSAID information and ADR-management  
Differences in reported provision of information regarding potential ADRs and how to prevent 
or manage them were also found for the different classes of NSAID. For non-selective 
NSAIDs, pharmacists claimed to provide information most frequently about GI ulcer (N=144, 
95.4%) and GI bleeding (N=97, 64.2%), but for selective NSAIDs, the most common ADRs 
mentioned were CV events (N=100, 74.1%), with other potential ADRs being mentioned by 
fewer than half, including high blood pressure (N=48, 35.6%). For non-selective NSAIDs, 
SKDUPDFLVWV¶PRVWFRPPRQadvice for preventing GI problems was to take after meals (N=138, 
94.5%), but many also claimed they would advise patients to use gastro-protective agents 
(N=98, 67.1%), switch to selective NSAIDs (N=91, 62.3%), or use other painkillers (N=79, 
54.1%). However, for selective NSAIDs, the most frequent advice given was to switch to other 
painkillers (N=95, 67.4%), use a gastro-protective agent (N=73, 51.8%) or see a doctor (N=68, 
48.2%).  
(Insert Table 4) 
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Multivariate analysis found that, for non-selective NSAIDs, male pharmacists were 
significantly less likely to inform patients about ADRs (Odd ratio (OR) 0.44, 95%CI 0.217-
0.900). However, communication about potential ADRs for users of selective NSAIDs was 
higher in pharmacy owners (OR 2.28, 95%CI 1.044-4.983) and in pharmacies with more than 
two pharmacists (OR 3.18, 95%CI 1.153-8.767). In contrast, pharmacists who had assistants 
were significantly less likely to inform about ADRs to selective NSAID users (OR 0.41, 95%CI 
0.199-0.856). However, there were no statistically significant factors which influenced the 
provision of ADR-management to patients. 
(Insert Table 5) 
 
Discussion 
This survey determined for the first time the self-reported practices of pharmacists working in 
accredited pharmacies across the whole of Thailand. While the majority of pharmacists claimed 
to screen patients for potential risk factors and provide patients with information about ADRs 
and their management, many pharmacists indicated they did not do so for all patients. 
Approximately 30% indicated they did not ask questions relating to history of NSAID use and 
almost half claimed not to screen older patients and ask about renal function. Slightly more 
pharmacists claimed to routinely screen patients for risk factors before supplying non-selective 
NSAIDs, while fewer did so for selective COX-2 NSAIDs. The risk factors for NSAIDs are 
well-known (Lanas  et al., 2009; Gargallo et al., 2014; Rafaniello et al., 2016) and apply to 
both selective and non-selective NSAIDs (Lanas  et al., 2009; Adams et al., 2011). Healthcare 
professionals should be aware of the need to both screen and monitor patients at risk.  
 
Community pharmacists are well placed to detect drug related problems (Paulino et al., 2004; 
Vinks et al., 2006; Niquille and Bugnon, 2010), but they can also play a key role in identifying 
high-risk patients and providing information, both of which can help to reduce NSAID 
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complications, such as acute renal failure (Pai, 2015). Because NSAIDs can be obtained with 
or without prescription, multiple NSAID use in individuals is common (Wilcox et al., 2005).  
Patients may not inform pharmacists about their medicines use or other relevant problems 
(LaCivita et al., 2009), therefore such screening questions are important. 
 
Only 40-60% of community pharmacists claimed to give advice on ADRs from 
NSAIDs, which is higher than has been claimed in previous studies in other countries (Tully et 
al., 2011; Alaqeel and Abanmy, 2015). Studies generally suggest that patients do not receive 
enough information about medicines from community pharmacists (Alotaibi and Abdelkarim, 
2015), and our own work in Thailand has confirmed that only 50% of patients using NSAIDs 
have received information on identifying, monitoring and managing adverse effects 
(Jarernsiripornkul et al., 2016). The differences in information provision found between 
different classes of NSAID appear unjustified, since both can result in adverse effects affecting 
both GI and CV system (Massó González et al., 2010). NSAIDs are often used long-term and 
in high doses, both of which can increase the risk of ADRs (Ritter et al., 2009; Turajane et al., 
2009), therefore patients should usually be advised to use them at low dose and for short 
duration, however, these basic points of information for preventing ADRs were not reported 
by our Thai community pharmacist respondents. 
Community pharmacists in Thailand are the main source of supply of NSAIDs and it is 
essential that all patients obtaining them are aware of the potential risks. Despite accredited 
pharmacies having high quality services guaranteed by the Pharmacy Council, this study found 
that patients may still not receive the desirable comprehensive service from these pharmacies 
in relation to these widely used medicines, which it is known result in many ADRs (Health 
Product Vigilance Center, 2018). Greater effort is needed to ensure that community pharmacy 
services in Thailand contribute more to the safe use of medicines, such as NSAIDs. Studies in 
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other countries show that the public trust NSAIDs, regarding them as harmless, particularly 
OTC NSAIDs, few believe themselves to have any risk factors for using these drugs, and show 
a lack of concern about potential adverse effects (Wilcox et al., 2005). Pharmacists could 
increase awareness of NSAID risks among their patients, carry out screening and evaluate 
patient risk factors and provide information to patients to ensure appropriate, safe use of these 
drugs.  
Limitations of the study 
Our study only included pharmacists who work in accredited pharmacies, which may be 
expected to provide better quality services than the non-accredited pharmacies constituting the 
large majority of pharmacies in Thailand. In addition, the response rate was approximately 
40% and no data were obtained about non-responding pharmacies. Therefore our results cannot 
be extrapolated to non-accredited pharmacies or to all accredited pharmacies across Thailand. 
It is likely that the proportion of pharmacists who do provide screening and information to 
patients may be considerably lower than our results suggest. Social desirability and recall bias 
may have occurred, in addition, the self-completed questionnaire required pharmacists to self-
report the frequency of their practices using only three options (regularly, occasionally, or 
never). 
Conclusion 
Risk screening and provision of ADR information and management for patients using NSAIDs 
was not universal practice in Thai accredited community pharmacists. Thus patients may be at 
risk of ADRs from NSAIDs obtained from pharmacies and they are also not fully informed 
about potential ADRs. Greater attention should be paid to the provision of medication safety 
information about NSAIDs by community pharmacists, particularly in patients who use these 
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Table 1 Characteristics of community pharmacist respondents  
Characteristics Total (N=159) 
Female 104 (65.4) 
Age  
Mean r S.D., years  37.2±11.42 
Median (IQR) 35 (28-45) 
(Min-Max) (23-73) 
Educational level  
%DFKHORU¶VGHJUHH 117 (73.6) 
+LJKHUWKDQEDFKHORU¶VGHJUHH 42 (26.4) 
Practice experience  
< 5 years 67 (42.1) 
\HDUV 92 (57.9) 
Pharmacy owners 90 (56.6) 
Type of drugstore  
Independently owned 114 (71.7) 
Franchise/Chain  45 (28.3) 
Location of drugstore  
Rural area 34 (21.4) 
Urban area 125 (78.6) 
No. of pharmacist in pharmacy  
Meanr S.D., persons 2.0±2.04 
Median (IQR) 1 (1-2) 
(Min-Max) (1-15) 
Have assistant in pharmacy  
Not have 53 (34.0) 
Have 103 (66.0) 
No. of visits per day  
Mean  r S.D., persons 105.9±127.93 
Median (IQR) 80 (50-120) 
(Min-Max) () 
Working time per day  
Mean  r S.D., hours 9.9±2.39 
Median (IQR) 10 (8-12) 
(Min-Max) (2.5-18) 








Table 2 Frequency of FRPPXQLW\SKDUPDFLVWV¶self-reported practices in supplying NSAIDs 
Practice roles No. of community pharmacists (%) 
Regularlya Occasionallyb Neverc Total 
Screening for risk factors     
      For non-selective NSAIDs 150 (95.5) 7 (4.5) 0 (0) 157 (100.0) 
      For selective COX-2 NSAIDs 85 (56.3) 61 (40.4) 5 (3.3) 151 (100.0) 
Assessment of the necessity for using 
NSAIDs 
109 (70.3) 43 (27.7) 3 (1.9) 155 (100.0) 
ADR communication     
      For non-selective NSAIDs 98 (63.2) 56 (36.1) 1 (0.7) 155 (100.0) 
      For selective COX-2 NSAIDs 55 (36.9) 86 (57.7) 8 (5.4) 149 (100.0) 
Advice to manage and prevent adverse effects    
      For non-selective NSAIDs 118 (79.7) 28 (18.9) 2 (1.4) 148 (100.0) 
      For selective COX-2 NSAIDs 86 (58.9) 57 (39.0) 3 (2.1) 146 (100.0) 
Asking about current drug use /herbs 
/supplements 
48 (30.8) 95 (60.9) 13 (8.3) 156 (100.0) 
Advice on what should/should not do while 
taking NSAIDs 
116 (73.4) 41 (26.0) 1 (0.6) 158 (100.0) 
Notes: 
a  Regularly was defined as providing practice to all patients 
b  Occasionally was defined as providing practice to some patients 



















Table 3 Frequency of self-reported risk factor screening for specific conditions 
Details on screening of risk factors  
No. of community pharmacists (%) 
Regularly Occasionally Total 
Dispensing of non-selective NSAIDs a    
History of GI ulcer/bleeding 100 (71.4) 40 (28.6) 140 (95.9) 
Multiple NSAIDs/long-term/high dose 79 (71.8) 31 (28.2) 110 (75.3) 
History of renal impairment 71 (74.7) 24 (25.3) 95 (65.1) 
Older age 59 (73.8) 21 (26.2) 80 (54.8) 
History of  liver impairment 47 (82.5) 10 (17.5) 57 (39.0) 
Taking a steroid drug 42 (79.2) 11 (20.8) 53 (36.3) 
Dispensing of selective COX-2 NSAIDs b   
History of GI ulcer/bleeding 64 (57.7) 47 (42.3) 111 (78.7) 
Cardiovascular disease 67 (62.6) 40 (37.4) 107 (75.9) 
Multiple NSAIDs/long-term/high dose 58 (63.7) 33 (36.3) 91 (64.5) 
History of renal impairment 54 (67.5) 26 (32.5) 80 (56.7) 
Older age 51 (70.8) 21 (29.2) 72 (51.1) 
History of  liver impairment 41 (73.2) 15 (26.8) 56 (39.7) 
Notes: 
a  The question was answered  by 146 community pharmacists  















Table 4 Most frequently reported advice concerning management of or protection against 
ADRs from NSAIDs 
Advice on management 
No. of community pharmacists (%) 
Regularly Occasionally Total 
For non-selective NSAIDsa    
Taking NSAIDs after meal 115 (83.3) 23 (16.7) 138 (94.5) 
Using with gastroprotective agents 82 (83.7) 16 (16.3) 98 (67.1) 
Switching to selective COX-2 NSAIDs 75 (82.4) 16 (17.6) 91 (62.3) 
Switching to other painkillers 68 (86.1) 11 (13.9) 79 (54.1) 
Stop taking NSAIDs 33 (80.5) 8 (19.5) 41 (28.1) 
For selective COX-2 NSAIDsb    
Switching to other pain killers 63 (66.3) 32 (33.7) 95 (67.4) 
Using gastroprotective agents 45 (61.6) 28 (38.4) 73 (51.8) 
Consult with physicians 45 (66.2) 23 (33.8) 68 (48.2) 
Stop taking NSAIDs 32 (68.1) 15 (31.9) 47 (33.3) 
Dose reduction 20 (66.7) 10 (33.3) 30 (21.3) 
Notes: 
a  The question was answered  by 146 community pharmacists  


















No. of pharmacist (%) Odds 




Provision of ADR information related to users of non-selective NSAIDs b 
Sex      
Female 69 (70.41) 32 (56.14) 1   
Male 29 (29.59) 25 (43.86) 0.442 0.217,0.900 0.024 
Have assistant in pharmacy    
No 37 (38.14) 15 (27.27) 1   
Yes 60 (61.86) 40 (72.73) 0.493 0.230,1.055 0.068 
Provisionof ADR informationrelated toXVHUVRIselective COX-2NSAIDs c 
Pharmacy owner      
No 18 (32.73) 46 (48.94) 1   
Yes 37 (67.27) 48 (51.06) 2.280 1.044,4.983 0.039 
No. of pharmacists      
1-2 persons 43 (78.18) 84 (89.36) 1   
> 2 persons 12 (21.82) 10 (10.64) 3.179 1.153,8.767 0.025 
Have assistant in pharmacy     
No 26 (47.27) 23 (25.27) 1   
Yes 29 (52.73) 68 (74.73) 0.412 0.199,0.856 0.017 
Notes: 
a Frequency of ADR information provision  defined as providing ADR information regularly or not 
regularly 
bAdjusted for sex, age, practice experience, number of pharmacist, and have assistant in pharmacyin 
logistic regression model. 
cAdjusted for pharmacy owner, number of pharmacist, have assistant in pharmacy, and working time
in logistic regression model. 
 
 
 
 
 
 
